移植患者腹壁疝修补术后结局的病例匹配回顾性研究
本研究回顾性分析2018年1月至2024年3月接受腹壁疝修补的移植患者,按1:1病例匹配非移植患者,比较30天并发症与疝复发。结果显示两组30天手术部位感染和手术部位事件无差异,但移植组疝复发率数值更高;移植组内非中线疝、使用可吸收补片及西罗莫司等免疫抑制方案与更高复发相关。
要点
- 移植患者腹壁疝修补后30天手术部位并发症与匹配非移植患者无显著差异。
- 移植组疝复发率数值高于非移植组,但差异未达统计学显著。
- 移植患者中非中线疝、可吸收补片及西罗莫司等免疫抑制与更高复发相关。
核心结论
- 在病例匹配队列中,移植患者腹壁疝修补后30天手术部位感染和手术部位事件未增加,但疝复发率数值更高。
- 移植患者中中线疝修补未观察到不良结局风险增加,而非中线腹壁疝显著影响结局。
研究设计与样本
- 回顾性队列研究,使用前瞻性维护数据库,纳入2018年1月至2024年3月接受腹壁疝修补的既往肝、肾、心、肺或胰岛细胞移植患者。
- 共纳入253例患者,其中32例移植患者与32例非移植患者进行1:1病例匹配。
- 主要结局为30天并发症及平均随访13个月的疝复发。
主要发现
- 移植组与非移植组30天手术部位事件(SSO)无差异(p=0.13),手术部位感染(SSI)无差异(p=0.16)。
- 疝复发率在移植组为12.1%,非移植组为3.0%(p=0.16)。
- 移植组内,可吸收补片者复发率23.1% vs 不可吸收补片2.9%(p=0.06)。
- 移植组内,非中线疝复发率25.0% vs 中线疝0.0%(p=0.02)。
- 移植组内,使用西罗莫司或其他免疫抑制药物者复发率40.0%,他克莫司者15.4%,无相应药物者0.0%(p=0.01);2例复发为桥接修补。
关键数值与推荐
- 移植患者被归类为腹壁疝工作组2类,提示不良结局风险较高。
临床怎么用
- 移植患者腹壁疝修补可考虑中线修补,其不良结局风险未见增加。
- 对移植患者非中线腹壁疝应加强关注,因其与更高疝复发相关。
- 移植患者补片选择及免疫抑制方案(如西罗莫司)可能影响疝复发,需个体化评估。
局限性
- 回顾性研究设计。
- 移植组样本量较小(32例匹配患者)。
- 平均随访13个月,可能不足以评估长期复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplant patients undergoing ventral hernia repair are classified as Ventral Hernia Working Group 2, indicating higher risk for adverse outcomes. This study assessed perioperative outcomes in transplant patients undergoing ventral hernia repair compared to a case-matched cohort of non-transplant patients. METHODS: A retrospective review was conducted using a prospectively maintained database of patients who underwent ventral hernia repair between January 2018 and March 2024. Inclusion criteria included prior liver, kidney, heart, lung, or islet cell transplant patients. A 1:1 case-match was performed. Primary outcomes included 30-day complications and hernia recurrence at a mean follow-up of 13 months. RESULTS: In total, 253 patients were included. Thirty-two transplant patients were matched to 32 patients in the control group. No difference was observed in 30-day postoperative complications including SSOs (p = 0.13) and SSIs (p = 0.16). The hernia recurrence rate was 12.1 and 3.0% in the transplant and non-transplant cohorts, respectively (p = 0.16). In the transplant cohort alone, hernia recurrence was higher in patients receiving absorbable mesh compared to non-absorbable mesh (23.1% vs. 2.9%, p = 0.06), non-midline versus midline hernias (25.0% vs. 0.0%, p = 0.02), and patients on sirolimus or other immunosuppression medications versus tacrolimus (40.0% vs. 15.4% vs. 0.0%, p = 0.01). Two of the recurrences were bridged repairs. CONCLUSIONS: In our study we did not observe increased risk of adverse outcomes in midline hernia repairs in transplant patients. However, non-midline ventral hernias significantly impact ventral hernia outcomes in transplant patients. In a case-matched cohort, there was no increased rates of SSI or SSO in transplant patients compared to nontransplant patients, but hernia recurrence rates were higher in the transplant cohort.
引用
- Hlavinka WJ, Akkihal KS, Dickerson KM, et al. Postoperative outcomes in transplant patients undergoing ventral hernia repair. Surg Endosc. 2025. PMID: 41003775. doi:10.1007/s00464-025-12249-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。